Neuromyotonia and myasthenia gravis in the absence of thymoma.
Antelli
A
A
Spengos
K
K
Zambelis
T
T
Pandis
D
D
Tsivgoulis
G
G
Zis
V
V
D000368:Aged; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D006801:Humans; D020386:Isaacs Syndrome / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D051667:Kv1.6 Potassium Channel; D008297:Male; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D051637:Shaker Superfamily of Potassium Channels / Q000276:immunology; D013945:Thymoma; D013953:Thymus Neoplasms
D002800:Cholinesterase Inhibitors; C064389:KCNA6 protein, human; D051667:Kv1.6 Potassium Channel; D051637:Shaker Superfamily of Potassium Channels; D011729:Pyridostigmine Bromide